Alfacell Corporation Financial Statements
Alfacell Corporation Financial Information
| Company Type | Public Single Location |
|---|---|
| Fiscal Year-End | July |
| Investor Relations | Company Web Site |
This data is provided as per license from EDGAR Online
Alfacell Corporation Income Statement
| 2007 | 2006 | 2005 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 0.1 | 0.2 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (9.6) | (8.1) | (6.7) |
| Total Net Income ($ mil.) | (8.8) | (7.8) | (6.5) |
| Diluted EPS (Net Income) | (0.19) | (0.21) | (0.18) |
Alfacell Corporation Quarterly Statements
| Quarter Ending Apr 08 | Quarter Ending Jan 08 | Quarter Ending Oct 07 | |
|---|---|---|---|
| Revenue ($ mil.) | 0.0 | 0.0 | 0.0 |
| Gross Profit ($ mil.) | -- | -- | -- |
| Operating Income ($ mil.) | (5.1) | (3.5) | (2.8) |
| Total Net Income ($ mil.) | (5.0) | (1.7) | (2.7) |
| Diluted EPS (Net Income) | (0.10) | (0.04) | (0.06) |
Alfacell Corporation Financial Ratios
| Company | Industry Median |
Market Median1 |
|
|---|---|---|---|
| Price/Sales Ratio | -- | 3.81 | 1.53 |
| Price/Earnings Ratio | -- | 16.07 | 15.12 |
| Price/Book Ratio | -- | 2.80 | 1.46 |
| Price/Cash Flow Ratio | -- | 11.72 | 9.52 |
1 Public companies trading on the New York Stock Exchange, the American Stock Exchange, and the NASDAQ National Market.
Detailed Alfacell Corporation Financial Ratios
Alfacell Corporation Competitive Intelligence
| Eli Lilly | ImmunoGen | Merck | |
|---|---|---|---|
| Annual Sales ($ mil.) | 18,633.5 | 38.2 | 24,197.7 |
| Employees | 40,600 | -- | 59,800 |
| Market Cap ($ mil.) | 54,199.6 | 192.2 | 78,520.0 |
Competitive Landscape
